Background PTPRZ1-MET fusion was reported to associate with glioma progression from low-grade to high-grade glioma,which was a target by a MET inhibitor vebreltinib.However,little is known about the further efficacy o...Background PTPRZ1-MET fusion was reported to associate with glioma progression from low-grade to high-grade glioma,which was a target by a MET inhibitor vebreltinib.However,little is known about the further efficacy of vebreltinib among more glioma patients.This trial aims to evaluate the safety and efficacy of vebreltinib enteric-coated capsules in the treatment of sGBM/IDH mutant glioblastoma patients with the ZM fusion gene.Methods This multicentric,randomized,open-label,controlled trial plans to include 19 neurosurgical centers and recruit 84 sGBM or IDH mutant glioblastoma patients with the ZM fusion gene.This trial enrolls sGBM or IDH mutant glioblastoma patients with the inclusion criteria and without the exclusion criteria.It was registered with chinadrugtrials.org.cn(CTR20181664).The primary efficacy endpoint is overall survival(OS).The secondary endpoints are progression-free survival(PFS)and objective response rate(ORR).Discussion If proven effective,this targeted multifaceted intervention protocol will be extended for more glioma patients as a protocol to evaluate the safety and efficacy of MET inhibitors.Trial registration It was registered with chinadrugtrials.org.cn(CTR20181664).展开更多
Objective： To summary the recent advances in molecular research of glioblastoma （GBM） and current trends in personalized therapy of this disease.Data Sources： Data cited in this review were obtained mainly from Pu...Objective： To summary the recent advances in molecular research of glioblastoma （GBM） and current trends in personalized therapy of this disease.Data Sources： Data cited in this review were obtained mainly from PubMed in English up to 2015, with keywords ＆quot;molecular＆quot;, ＆quot;genetics＆quot;, ＆quot;GBM＆quot;, ＆quot;isocitrate dehydrogenase＆quot;, ＆quot;telomerase reverse transcriptase＆quot;, ＆quot;epidermal growth factor receptor＆quot;, ＆quot;PTPRZ1-MET＆quot;, and ＆quot;clinical treatment＆quot;.Study Selection： Articles regarding the morphological pathology of GBM, the epidemiology of GBM, genetic alteration of GBM, and the development of treatment for GBM patients were identified, retrieved, and reviewed.Results： There is a large amount of data supporting the view that these recurrent genetic aberrations occur in a specific context of cellular origin, co-oncogenic hits and are present in distinct patient populations.Primary and secondary GBMs are distinct disease entities that affect different age groups of patients and develop through distinct genetic aberrations.These differences are important, especially because they may affect sensitivity to radio-and chemo-therapy and should thus be considered in the identification of targets for novel therapeutic approaches.Conclusion： This review highlights the molecular and genetic alterations of GBM, indicating that they are of potential value in the diagnosis and treatment for patients with GBM.展开更多
基金funded by The National Key Research and Development Program of China(2019YFE0109400)National Natural Science Foundation of China(No.81972337 and No.81802994)+1 种基金Beijing Natural Science Foundation(No.JQ20030)Outstanding Young Talents of the Capital Medical University(No.B2101)
文摘Background PTPRZ1-MET fusion was reported to associate with glioma progression from low-grade to high-grade glioma,which was a target by a MET inhibitor vebreltinib.However,little is known about the further efficacy of vebreltinib among more glioma patients.This trial aims to evaluate the safety and efficacy of vebreltinib enteric-coated capsules in the treatment of sGBM/IDH mutant glioblastoma patients with the ZM fusion gene.Methods This multicentric,randomized,open-label,controlled trial plans to include 19 neurosurgical centers and recruit 84 sGBM or IDH mutant glioblastoma patients with the ZM fusion gene.This trial enrolls sGBM or IDH mutant glioblastoma patients with the inclusion criteria and without the exclusion criteria.It was registered with chinadrugtrials.org.cn(CTR20181664).The primary efficacy endpoint is overall survival(OS).The secondary endpoints are progression-free survival(PFS)and objective response rate(ORR).Discussion If proven effective,this targeted multifaceted intervention protocol will be extended for more glioma patients as a protocol to evaluate the safety and efficacy of MET inhibitors.Trial registration It was registered with chinadrugtrials.org.cn(CTR20181664).
文摘Objective： To summary the recent advances in molecular research of glioblastoma （GBM） and current trends in personalized therapy of this disease.Data Sources： Data cited in this review were obtained mainly from PubMed in English up to 2015, with keywords ＆quot;molecular＆quot;, ＆quot;genetics＆quot;, ＆quot;GBM＆quot;, ＆quot;isocitrate dehydrogenase＆quot;, ＆quot;telomerase reverse transcriptase＆quot;, ＆quot;epidermal growth factor receptor＆quot;, ＆quot;PTPRZ1-MET＆quot;, and ＆quot;clinical treatment＆quot;.Study Selection： Articles regarding the morphological pathology of GBM, the epidemiology of GBM, genetic alteration of GBM, and the development of treatment for GBM patients were identified, retrieved, and reviewed.Results： There is a large amount of data supporting the view that these recurrent genetic aberrations occur in a specific context of cellular origin, co-oncogenic hits and are present in distinct patient populations.Primary and secondary GBMs are distinct disease entities that affect different age groups of patients and develop through distinct genetic aberrations.These differences are important, especially because they may affect sensitivity to radio-and chemo-therapy and should thus be considered in the identification of targets for novel therapeutic approaches.Conclusion： This review highlights the molecular and genetic alterations of GBM, indicating that they are of potential value in the diagnosis and treatment for patients with GBM.
